DifGen Pharmaceuticals Announces First Major European Milestone with Successful Completion of Decentralised Procedure for Tafamidis 61 mg Capsules
Significant regulatory achievement marks an important step in DifGen's European expansion and strengthens its foundation for strategic partnerships MIRAMAR, Fla., Oct. 27, 2026 /PRNewswire/ -- DifGen Pharmaceuticals LLC ("DifGen"), a U.S.-based pharmaceutical company focused on the...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.